Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$14.59
+0.07 (+0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-164.1M · quality 28.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.0B
P/E
69.5x
↑EV/EBITDA
14.8x
↑ROE
3.4%
↑Gross Margin
29.6%
↓Debt/Equity
1.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.4%
FCF CAGR
-63.5%
FCF margin
0.6%
FCF / Net income
0.50x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.50B · net income $120.6M · FCF $60.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.50B | $10.50B | $12.39B | $15.62B | $14.13B |
| Net Income | $120.6M | $120.6M | $26.7M | $822.1M | $354.4M |
| EBITDA | $830.8M | $830.8M | $887.3M | $1.60B | $1.03B |
| EPS | 0.22 | 0.22 | 0.05 | 1.48 | 0.64 |
| Gross Margin | 29.6% | 29.6% | 39.3% | 48.6% | 45.4% |
| Operating Margin | 4.1% | 4.1% | 4.9% | 8.5% | 5.7% |
| Net Margin | 1.1% | 1.1% | 0.2% | 5.3% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 1.55 | 1.55 | 1.46 | 1.17 | 1.48 |
| Current Ratio | 0.74 | 0.74 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $60.7M | $60.7M | $-1.46B | $-164.1M | $1.25B |
| Returns | |||||
| ROE | 3.4% | 3.4% | 0.8% | 22.7% | 11.5% |
| Valuation | |||||
| P/E | 69.48 | 69.48 | 448.20 | 31.07 | 48.22 |
| EV/EBITDA | 14.84 | 14.84 | 18.29 | 17.37 | 18.78 |
| P/B | 2.28 | 2.28 | 3.42 | 7.05 | 5.53 |
| Growth & Yield | |||||
| Revenue Growth | -15.2% | -15.2% | -20.7% | 10.6% | — |
| EPS Growth | 340.0% | 340.0% | -96.6% | 131.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
80.5%
EPS terminal req.
$1.29
Spread vs growth
259.5%
5Y implied EPS CAGR
48.1%
EPS terminal req.
$1.57
Spread vs growth
291.9%
10Y implied EPS CAGR
27.6%
EPS terminal req.
$2.52
Spread vs growth
312.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.4%
Start / end P/E
438.0x → 66.3x
EPS bridge
0.05 → 0.22
Residual
-288.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.